Aureate: Enzalutamide tablets and Dydrogesterone tablets are proposed for selection in the 12th batch of national drug procurement.

Aureate announced that the company participated in the twelfth batch of national centralized drug procurement bidding. Enzalutamide tablets and dydrogesterone tablets are expected to be selected for the twelfth batch of centralized volume procurement, with the procurement period running from the execution date of the selection results until December 31, 2029. In 2025, the company's domestic sales revenue from dydrogesterone tablets is expected to be approximately 184 million yuan, accounting for 10.86% of the annual revenue for 2025.